EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 299 filers reported holding EXELIXIS INC in Q1 2018. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $19,456,842 | +32.6% | 865,903 | +40.0% | 0.01% | +20.0% |
Q1 2024 | $14,678,239 | -1.4% | 618,552 | -0.3% | 0.01% | -16.7% |
Q4 2023 | $14,886,394 | +10.8% | 620,525 | +0.9% | 0.01% | 0.0% |
Q3 2023 | $13,435,936 | +23.5% | 614,917 | +9.7% | 0.01% | +20.0% |
Q2 2023 | $10,882,877 | 0.0% | 560,684 | 0.0% | 0.01% | 0.0% |
Q1 2023 | $10,882,877 | +23.1% | 560,684 | +1.7% | 0.01% | 0.0% |
Q4 2022 | $8,839,883 | -99.9% | 551,115 | +4.5% | 0.01% | 0.0% |
Q3 2022 | $8,273,017,000 | -33.4% | 527,616 | -11.6% | 0.01% | -28.6% |
Q2 2022 | $12,430,747,000 | +5.2% | 597,058 | +14.5% | 0.01% | +40.0% |
Q1 2022 | $11,816,466,000 | +29.7% | 521,238 | +4.6% | 0.01% | +66.7% |
Q4 2021 | $9,111,758,000 | -7.2% | 498,455 | +7.3% | 0.00% | -25.0% |
Q3 2021 | $9,822,551,000 | +6.0% | 464,643 | -8.6% | 0.00% | 0.0% |
Q2 2021 | $9,262,938,000 | -16.2% | 508,394 | +4.0% | 0.00% | -20.0% |
Q1 2021 | $11,047,684,000 | +5.1% | 489,052 | -6.7% | 0.01% | 0.0% |
Q4 2020 | $10,515,616,000 | +12.3% | 523,947 | +36.9% | 0.01% | 0.0% |
Q3 2020 | $9,360,855,000 | +5.9% | 382,857 | +2.8% | 0.01% | 0.0% |
Q2 2020 | $8,838,544,000 | +11.8% | 372,306 | -18.9% | 0.01% | -16.7% |
Q1 2020 | $7,903,792,000 | +13.9% | 458,989 | +16.6% | 0.01% | +50.0% |
Q4 2019 | $6,937,858,000 | +10.3% | 393,749 | +10.7% | 0.00% | 0.0% |
Q3 2019 | $6,288,468,000 | -10.5% | 355,582 | +8.1% | 0.00% | -20.0% |
Q2 2019 | $7,029,191,000 | -12.0% | 328,928 | -2.0% | 0.01% | -16.7% |
Q1 2019 | $7,989,706,000 | +35.9% | 335,702 | +12.4% | 0.01% | +20.0% |
Q4 2018 | $5,877,238,000 | -77.7% | 298,792 | -79.9% | 0.01% | -75.0% |
Q3 2018 | $26,323,680,000 | -23.1% | 1,485,535 | -6.6% | 0.02% | -23.1% |
Q2 2018 | $34,245,507,000 | +13.1% | 1,591,334 | +16.4% | 0.03% | +8.3% |
Q1 2018 | $30,284,434,000 | -33.1% | 1,367,243 | -8.1% | 0.02% | -36.8% |
Q4 2017 | $45,243,560,000 | +24.9% | 1,488,275 | -0.4% | 0.04% | +15.2% |
Q3 2017 | $36,210,379,000 | -16.7% | 1,494,444 | -15.3% | 0.03% | -21.4% |
Q2 2017 | $43,443,773,000 | +20.6% | 1,763,856 | +6.1% | 0.04% | +13.5% |
Q1 2017 | $36,021,303,000 | +143634.5% | 1,662,266 | -1.1% | 0.04% | +32.1% |
Q4 2016 | $25,061,000 | -5.6% | 1,680,838 | -19.0% | 0.03% | -3.4% |
Q3 2016 | $26,534,000 | +71.8% | 2,074,585 | +4.9% | 0.03% | +70.6% |
Q2 2016 | $15,442,000 | +2355.0% | 1,977,251 | +1157.6% | 0.02% | +1600.0% |
Q1 2016 | $629,000 | -24.9% | 157,222 | +5.9% | 0.00% | 0.0% |
Q4 2015 | $837,000 | +27.6% | 148,460 | +27.0% | 0.00% | 0.0% |
Q3 2015 | $656,000 | +100.0% | 116,924 | +34.1% | 0.00% | – |
Q2 2015 | $328,000 | +52.6% | 87,194 | +4.1% | 0.00% | – |
Q1 2015 | $215,000 | +133.7% | 83,794 | +30.7% | 0.00% | – |
Q4 2014 | $92,000 | -6.1% | 64,094 | 0.0% | 0.00% | – |
Q3 2014 | $98,000 | -54.8% | 64,094 | 0.0% | 0.00% | – |
Q2 2014 | $217,000 | -4.4% | 64,094 | 0.0% | 0.00% | – |
Q1 2014 | $227,000 | -42.2% | 64,094 | 0.0% | 0.00% | – |
Q4 2013 | $393,000 | +6.8% | 64,094 | +1.3% | 0.00% | – |
Q3 2013 | $368,000 | +28.2% | 63,294 | 0.0% | 0.00% | – |
Q2 2013 | $287,000 | – | 63,294 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |